posted 07-17-2005 09:26 PM         

Merck & Co., Inc. is sponsoring a clinical trial for patients with relapsed Diffuse Large B Cell Lymphoma (DLBCL) throughout the United States and in selected ex-US countries.

This study is open to patients diagnosed with advanced Diffuse Large B Cell Lymphoma who have progressive, persistent, or recurrent disease following standard first line therapy with CHOP (or equivalent anthracycline-containing regimen) and at least one systemic salvage regimen (including but not limited to autologous hematopoietic stem cell transplant). All patients in this non-randomized, open-label, Phase IIb study will receive the oral histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid, SAHA).

In the United States, participating study sites are located in the following states:

Alabama
New Jersey
California
New York
Colorado
North Carolina
Connecticut
Pennsylvania
Illinois
Tennessee
Massachusetts
Texas
Michigan
Washington, DC
Nebraska

More information about this study can be found at: http://clinicaltrials.gov (Study ID: 2004_029 NCT00097929), or http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx (Protocol ID: 2004_029 )

To refer patients for evaluation for inclusion in this protocol,
please call 1-888-577-8839 (toll free).

Please feel free to forward this message to other health care providers who might be interested in learning more about the study and/or referring patients into this study.

Respectfully,